Company Overview and News
Over recent months, the share prices of two companies involved in supplying services to the alternative energy sector when it comes to fueling light, medium, and heavy-duty vehicle moved higher. Both Clean Energy Fuels Corporation (CLNE) and Westport Fuel Systems (WPRT) have moved appreciably higher from their lows. However, they remain at a fraction of the highs reached in 2012.
FP CLNE 2338 WEICF WEICY
2018-09-03 zacks - 1
Ballard Power Systems, Inc. (BLDP - Free Report) has entered into a definitive agreement with Revision Military Ltd., a private U.S.-based company, to sell certain non-core assets of its subsidiary, Protonex, with regard to its Power Manager business. The company will receive a total of $16 million in cash as sale consideration. However, it will still retain certain assets related to fuel cell propulsion systems for military and commercial unmanned vehicles.
BLD 2338 FCELB WEICF DDAIF PLUG FCEL BLDP WEICY
Clean Energy Fuels Corporations (CLNE) and Westport Fuel Systems (WPRT) are companies involved in supplying trucks and commercial vehicles with cleaners fuels. CLNE provides natural gas as an alternative fuel for vehicle fleets across the United States and Canada. The company designs, builds, and maintains fueling stations and sells and services natural gas fueling compressors and other equipment used in CNG and LNG stations.
FP CLNE 2338 WEICF WEICY
2018-08-29 thestar - 3
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
2338 WEICF WEICY BLDP
Westport Fuel Systems Inc. (WPRT - Free Report) has entered a definitive agreement with China’s Weichai Westport Inc. (“WWI”). With WWI, Westport Fuel will develop and commercialize natural gas engine based on one of Weichai Power Co., Ltd.’s (Weichai Power) heavy-duty engine platforms. Enabled with Westport Fuel’s HPDI 2.0 technology, this heavy-duty natural gas engine will cater to the Chinese market.
CMQMY OSK 2338 WEICF URBN PBB CMI PSEC WEICY
Shares of Ballard Power Systems Inc. BLDP, -2.00% and Westport Fuel Systems Inc. WPRT, +0.70% soared in premarket trade Wednesday, after the companies announced deals with affiliates of Weichai Holding Group Inc., a China-based automobile and equipment manufacturing company. Ballard's stock shot up 22% after the clean energy company said it entered into a collaboration with Weichai Power Co. Ltd. WEICY, +2.
BLD 2338 WEICF WEICY BLDP
VANCOUVER, British Columbia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. (“Westport Fuel Systems”) (TSX:WPRT / Nasdaq:WPRT) announced today that it has entered into definitive development and supply agreements with Weichai Westport Inc. (“WWI”) to develop, market, and commercialize a heavy-duty, natural gas engine featuring the Westport HPDI 2.0™ technology, based on one of Weichai Power Co.
2338 KIGRY WEICF WEICY
Commercialisation milestones will provide the near-term catalyst for Ceres Power Holdings PLC (LON:CWR), the German broker Berenberg said back in July 2017.
2338 WEICF CPWHF WEICY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...